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risk reduction at discharge (age-adjusted RR 0.68, 95% Cl 0.64-0.72) to 1.2% reduction 
at one year after the MI (age adjusted RR 0.83, 95% Cl 0.79-0.87). These trends were 
magnified among patients with non-Q Ml. Different patient demographics, shorter length 
of stay and higher number of potentially unstable non-Q Ml’s resulting from thrombolysis 
may account for part of the increase in post discharge mortality in 1996. 
Conclusions The increased monality after discharge of MI patients in the thrombolytic era 
diminished the benefit of improved inpatient care. For each 1,000 MI admissions, 38 
more patients were discharged alive in 1996 than in 1986 while one year later only 12 
more were alive. While in-hospital mortality for non-Q MI remained lower (one fourth to 
one third) than that of Cl Ml from 1986 to 1996. the one year mortality for non-Q Ml was 
the same as Q Ml in 1996. 
1126-101 Cytomegalovirus: Strength of Antibody Response and 
Its Relationship to Risk of Mortality Among Patients 
With Angiographic Coronary Disease 
Beniamin D. Home, Joseph B. Muhlestein. John F. Carlquist. Dale G. Renlund. Tami L. 
Bair, Jeffrey L. Anderson, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake 
City, UT 
Background: IgG seropositivity to cylomegalovirus (CMV) has been shown in a variety 
of studies to predict future outcome in patients with coronary heart disease (CHD). 
Seropositivity is usually defined by an arbitrary threshold of antibody response. However, 
among CHD patients, whether the strength of antibody response to CMV infection is pra- 
dictive of future outcome is unknown. 
Methods The Registry of the Intermountain Heart Collaborative Study provided a cohort 
of consenting patients (N=2,797) with significant, angiographically-defined atherosclero- 
sis. CMV IgG serology was measured as an immune status ratio (ISR) value by ELISA 
(manufacturer’s criterium for seropositivity is ISR=l.l). Patients were followed for up to 
7.9 years (mean: 3.3r2.0 years) to determine the incidence of all-cause moltality. The 
predictive value for mortality of the continuous distribution of ISR levels was evaluated 
compared to slmpk seropositivity Cox regression adjusted for 24 demographics, CHD 
risk factors, comorbidities, and treatments. 
Results Average age was 65+11 years: 76% were male. A significant linear association 
with mortality was found for the continuous ISR values (hazard ratio (HR]=l.O9/ISR unit, 
p&001). Recursive partitioning confirmed the manufacturer’s threshold for seropositivily 
as an appropriate decision point for CHD risk (seronegative: death=lO%; seropositive: 
death=l9%; fully adjusted Cox: p=O.O16, HR=1.3. 95% CI=l.l-1.7). However, among 
seropositive patients it also revealed a second threshold (ISR=3.76) above which the risk 
of moltality was ameliorated, with death=22% for ISR=l.l-3.76 (n=964, p=O.O38 vs. 
seronagatlve, HR=l.4, Cl=l.O2-1.8) and death=l6% for ISR>3.76 (n=1168, p=O 30 vs. 
seronegative, H&1.2, CI=O.67-1.6). 
Conclusions In this large population of patients with coronary disease at baseline, CMV 
seropositivity was significantly predictive of future mortality. However, the risk was great- 
est for intermediate antibody levels and was ameliorated at higher levels. This raises new 
questions about the nature and complexity of the host immunologic response to CMV 
exposure and how it relates to determination of CHD risk. 
1126-l 02 Is COX-2 Inhibitor Use Associated With an Increased 
Rate of Recurrent Events Among Patients With a Recent 
Cardiovascular Event? 
Roberto A. Corws, Jr, John House, Nancy Drummond, William H. Downham. Steven P. 
Marso, Mid America Heart Institute, Kansas City, MO 
Backaround: Retrospective m&a-analyses have suggested that cyclooxygenase-2 
inhibitor (COX-2) use is associated with an increased risk of thrombotic cardiovascular 
events. 
Methods Patients hospitalized for an initial cardiovascular event (N-2876) were identi- 
fied from a large HMO database usmg specific ICD-9 codes for acute MI, unstable 
angina, or stroke (CVA). Patients with a prior history of cardiovascular or cerebrovascular 
disease were excluded from this analysis. Based on prescription data. patients were sub- 
divided based on active COX-2 use subsequent to the initial cardiovascular event. The 
primary endpoint of this study was the occurrence of cardiovascular mortality, re-infarc- 
tion, CVA, or acute peripheral arterial occlusion wthin one year of the primaly event. 
Regultg There were no significant demographic differences between pabents with 
(N=l70) and without (N=2706) COX-2 use Rates of recurrent cardiovascular events are 
demonstrated below: 
Conclusionr COX-2 use does not confer an increased risk of recurrent events following 
an initial cardiovascular event. Further prospective randomized trials are needed to con- 
firm these findings. 
1126-103 Predicting Early Coronary Revasculariration After an 
Acute Coronary Syndrome 
Jeffrev A. Gavard Bernard R. Chaitman, Shunta Sakai, Karen Stocke, Nicolas Danchin, 
Leif Erhardt. Eric Chi. Andreas Jessel, Richard Gallo, Pierre Theroux, for the GUARDIAN 
Investigators, St. Louis University School of Medicine, St. Louis, MO 
Background: Risk models to predict coronary revascularization (REVASC) within 6 
weeks after an acute coronary syndrome (ACS) may facilitate earlier triage. 
Methods: The GUARDIAN trial contained 4,233 ACS pts without persistent ST elevation. 
Baseline and post-randomization variables were compared between pts with and without 
REVASC. A multivariate logistic regression model was used to develop a REVASC risk 
score. 
Results: REVASC occurred in 1,239 (29.3%) pts. Final multivariate results (table). The 
6-week REVASC risk was 17.6%. 32.8%. and 46.0% for pts with risk scores ~3~4-5. and 
z6, respectively (p<O.OOl); 37.3%, 47.3%, and 15.3% of the pts were in each group. 
Conclusions: Risk scores identify ACS pts at higher risk for REVASC and may assist in 
early triage procedures. 
Univariate Analysis 
With Factor Without Factor 
Risk Factor 
Age ~65 
Male gender 
Multiracial 
N REVASC N REVASC 
(%) (%) 
2.03 32.5 2.19 26.3 
9 4 
2,88 31.8 1.34 23.8 
6 7 
56 48.2 3.92 29.2 
” 
L 
Angina 3,28 31.0 951 23.1 
2 
No CHF 3,65 30.5 582 21.6 
Hypercholesterolem 2,14 33.1 2,08 25.3 
ia 8 5 
Prior PTCA 553 43.2 3.67 27.0 
Serial T wave 1,36 31.7 2.01 24.3 
4 4 
Serial ST elevation 312 44.9 2,Ol 24.3 
4 
Serial Q wave 137 49.6 2,01 24.3 
4 
OR = odds ratio 
Multivariate 
Analysis 
OR ~ p-value 
1.23 co.01 
1.43 co.001 
2.43 co.01 
1.49 <O.OOl 
1.59 <O.OOl 
1.35 <O.cOl 
1.79 ~0.001 
1.50 <O.ool 
2.47 <0.001 
3.22 <O.cOl 
1126-104 Prediction of Two-Year Survival and Composite 
Endpoints Using the TM-7 Risk Score Extended by N- 
Terminal Pro-Brain Natriuretic Peptide Levels 
Rudolf Jarai, Robert Jarai, Ferenc Jarai, Nelly lordanova, Walter S. Speidl. Wolfgang 
Woloszczuk, Georg Geyer, Johann Wojta, Kurt Huber, University of Vienna, Vienna, 
Austria. Ludwig Boltzmann Institute for Experimental Endocrinology, Vienna, Austria 
Background: The TIMI- Risk Score is a useful risk stratification tool for identifvino , - 
patieits with unstable angina. The Brain Natriuretic Peptide (BNP) and the N-terminal 
fraament of it’s orohormone (N-terminal Brain Natriuretic Peotide. NBNP1 are strono. 
“. 
independent predictors of death in patients with acute myocardial infarction and unstable 
coronary disease. However, there exists at present no scoring system for the assess- 
ment of patient’s risk that combines clinical risk scores with one of these natriuretic pep- 
tides. 
Patients and methods: Plasma levels of the NBNP were determined in 145 consecutive 
patients (unstable angina and non-ST-elevation myocardial infarction; UA/NSTEMI) 
admitted to our clinic and were divided into three risk arouos accordina to their TIMI- 
score: high (6-7), medium (4-5) and low risk (l-3). With assistance of the data mining 
techniaue. decision tree (SPSS Inc.. USA). we extended these TIMI Risk orouos with the . 
patients NBNP levels. The so developed combined sconng system consists of 4 groups: 
very high (NBNP>O.G nmol/l), high (TIMI high or TIMI medium risk group and NBNP>0.33 
nmolll), medium (TIMI medium or TIMI low risk group and NBNP>0.33 nmolll) and low 
(TIMI low risk group). 
Results: The relatwe risk of death in the TIMI high, medium and low risk groups was 
30%, 10% and 2%, respectively (p<O.OOl, for trend). If the NBNP level was higher than 
0.33 nmolll (75 percentile) the relative risk of the TIMI groups increased to 44% in the 
high, to 31% in the medium and to 10% in the low risk group. If the NBNP level was 
below this cut-off level, the relative risk of death was 24%, 4% and ~1% in the respective 
TIMI groups. The relative risk of death in the combined TIMI-NBNP groups was 47%, 
20% 4%. and 1%. respectively (p<O.O005, for trend). The receiver operatmg characteris- 
tic (ROC) curve analysis for suwival was performed to test and to compare the predictive 
accuracy of the respective scoring systems. The area under the ROC-curve was 0.77 for 
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the TIMI score and 0.87 for the TIMI-NBNP score. Conclusion: Although the cohort of 
patients is relative small, we could demonstrate the importance of additional measure- 
ment of NBNP levels for risk stratification in patients with UAINSTEMI. 
1126-105 Serum Creatinine, Creatinine Clearance, and Long-Term 
Mortality Afler Non-ST Elevation Acute Coronary 
Syndrome Treated Very Early and Predominantly With 
Percutaneous Coronary Intervention 
Christian Mueller, Franz-Josef Neumann, Helmut Roskamm. Andre P. Perruchoud. 
Heinz J. Buettner, University Hospital, Easel, Switzerland, HewZentrum, Bad 
Krozingen, Germany 
Background: Very early revascularization is the most contemporary management strat- 
egy in non-ST-elevation acute coronary syndromes (NSTACS). Predictors of outcome 
with this strategy are poorly defmed. We sought to quantity the impact of baselme renal 
dysfunction on short and long-term mortality in patients with NSTACS treated with an 
very early invasive strategy. Methods: We conducted a prospective cohort study in 1400 
consecutive patients with NSTACS undergoing coronary angiography and subsequent 
coronary stenting of the culprit lesion as the primary revascularization strategy within 24 
hours of admission. Mortality in-hospital and at 3 years was stratified according to quar- 
tiles of serum creatinine and corrected creatinine clearance determined on admlssion. 
Results: Kaplan-M&r survival analysis demonstrated a cumulative 3.year survival of 
95.3% in the first (co.71 mg/dL), 95.1% in the second (0.71-0.84 mg/dL), 92.9% in the 
third (0.84-1.00 mg/dL), and 83.1% in the fourth quartile of serum creatinine (2 1.00 mgl 
dL) (p<O.OOl). For the quartiles of creatinine clearance (<68, 68-85, 85105, 2 105 ml./ 
min), cumulative 3-year survival was 82.0%, 91.3%, 95.7% and 96.9%, respectively 
(p<O.OOl). Patients in the highest quartile (t 1 .OO mg/dL) of serum creatinine wan? six 
times more likely to die in-hospital (hazard ratio 6.1, [95% Cl 2.6 to 14.1); pcO.001) and 
almost four times more likely to die during long-term follow-up (hazard ratio, 3.8 [Cl 2.4 to 
5.81; pcO.001). By multivariate Cox regression analysis, serum creatinine in the highest 
qualtile remained a strong independent predictor of mortality. Conclusion: Baseline 
renal dysfunction is a strong independent predictor of in-hospital and long-term mortality 
after NSTACS treated with very early revascularization. 
ORAL CONTRIBUTIONS 
827 Contemporary Issues in Primary 
Angioplasty on Acute Myocardial 
Infarction 
Monday, March 31, 2003, 4:00 p.m.-530 p.m. 
McCormick Place, Vista S406 A 
4:oo p.m. 
827-l How Important Is Time to Treatment With Primary 
Percutaneous Coronary Intervention for Acute 
Myocardial Infarction? Results From the CADILLAC 
Trial 
Bruce R. Brodie, David A. Cox. Thomas D. Stuckey, Mark Turco, Eulogio Garcia, John J. 
Griffin, Martin Fahy, James E. Tcheng, Cindy L. Grines, Roxana Mehran, Gregg W. 
Stone, LeBauer Cardiovascular Research Foundation, Greensboro, NC, Cardiovascular 
Research Foundation, New York, NY 
Background: Time to treatment is critlcally important with thrombolytic therapy, but may 
be less impoltant with primary PCI. 
Methods: The CADILLAC Trial enrolled pts with AMI ~12 hrs without shock who were 
randomized to stenting vs PTCA +I- abciximab. Treatment time data were available in 
2,002 pts. 
Resulb: Median (25” and 75m percentiles) time from symptom onset to ER was 1.8 hrs 
(1 .O, 3.4), from ER to balloon inflation (DB time) was 2.0 hrs (1.5, 2.7) and from symptom 
onset to balloon Inflation @perfusion time, AT) was 4.0 hrs (2.9, 6.1). RT (hrs) was 
longer at US sites (4.0 vs 3.7, p=O.O02), in women (4.6 YS 3.8, p<O.OOOl). diabetics (4.6 
vs 3.6, p<O.OOOl ), and pts with CFX infarcts (4.4 YS 3.9, p=O.O003). Mortality (30 day 
and 1 yr) was lowest with RT < 3 hrs and there was a trend for lower 1 yr re-infarction 
with RT < 3 hrs (Table). After 3 hrs. further treatment delays had little impact on mortality. 
DB times (cl .5 vs 1.5-2.0 vs >2.0-3.0 YS z.3.0 hrs ) had little effect on 1 yr mortality (3.4% 
vs 4.3% “s 4.2% “s 4.6%. p=NS). 
Conclusions: Early repelfusion (c 3 hrs) with primary PCI is associated with better 30 
day and 1 yr survival and a trend toward less m-infarction at 1 yr. Delays beyond 3 hrs 
have little effect on survival. These data emphasize the importance of early repeltuslon 
and have implications regarding pt triage and the mechanism of benefit of reperfusion 
therapy with primary PCI. 
TIMI 3 Flow Post-PC1 
Mortality (30 day) 
Mortality (1 year) 
Re-infarction (1 year) 
Stroke (1 year) 
*<3hrs vs >=3hrs 
c3 hrs 
(n=559) 
96.1% 
0.9% 
2.5% 
1 .4% 
0.5% 
March 19,2003 
3-6 hrs 
(n=930) 
95.3% 
2.3% 
4.5% 
2.6% 
0.3% 
>6hrs 
(n=513) 
96.0% 
2.2% 
4.8% 
3.3% 
0.6% 
p Value 
NS 
0.04 
0.04, 
0.06’ 
NS 
4:15 p.m. 
027-2 Baseline Features and Clinical Results in Patients 
Excluded From Randomization From a Large 
International Trial of Reperfusion Strategies in Acute 
Myocardial Infarction: The CADILLAC Registry 
Mark A. Turco, David A. Cox, Eulogio Garcia, James E. Tcheng, John J. Griffin, Giulio 
Guagliumi, Thomas D. Stuckey, John D. Carroll, Cindy L. Grines, Barry D. Rutherford. 
Steve Slack, Martin Fahy, Roxana Mehran, Alexandra J. Lansky, Gregg W. Stone, 
Center for Cardiac & Vascular Research and Washington Adventist Hospital, Takoma 
Park, MD, Cardiovascular Research Foundation and Lenox Hill Heart and Vascular 
Center, New York, NY 
Background:The randomized CADILLAC trial was performed to compare PTCA versus 
stenting with or without abciximab, in AMI patients of any age without cardiogenic shock 
presenting c12hrs from symptom onset. Patients meeting these criteria but who were 
excluded from randomization for a variety of pm-specified angiographic reasons were fol- 
lowed in an in-hospital registry. 
Aesults:Of 2,681 AMI pts consented, 599 (22%) were not randomized, most commonly 
because of extensive LM/9vessel disease (38%), vessel size <2.5mm or >3.75mm 
(23%), excessive tortuosity (17%), calcification (16%), unprotected LM or ostial disease 
(16%). or non-identifiable culprit (15%). Compared to randomized pts, those in the regis- 
try were more likely to be older (69 vs 52 yrs, p=O.O02), have prior Ml (20% vs 14%, 
p=O.OOOl), prior CABG (12% vs 2%, p<O.OOOl), 3-vessel disease (52% vs 15%, 
pcO.OOOl), lower LVEF (45% vs 50%, p=O.OOOl), and fewer inferior infarcts (47% vs 
56%. p=<O.OOi). Pts in the registry were treated either medically (38%), by PCI (39%) or 
wth CABG (23%). Comparative outcomes are reported below. 
In Hospital Outcome Registry Randomized P-Value 
NS99 N=2082 
Final TIMI 3 80% 95% <O.OOl 
Death 4.0% 1.6% 0.001 
Reinfarction 0.3% 0.2% NS 
Revascularization 14.0% 2.5% <O.OOl 
Stroke 0.5% 0.5% NS 
MACE 18.0% 4.6% <O.OOl 
Conclusions: Although 78% of consented pts (and 90% of those undergoing PCI) were 
randomized in CADILLAC. pts with AMI excluded from randomization on angiographic 
grounds comprised an extremely high risk cohort with multiple adverse baseline features, 
lower procedural success, and diminished event-free wvival. These data partly explain 
differences between AMI trials that randomize pts before versus after angiography. 
4:30 pm. 
827-3 Relationship Between Time-to-Reperfusion and 30-Day 
Mortality in Patients With ST-Segment Elevation 
Myocardial Infarction Treated With Primary Angioplasty 
Giuseppe De Luca, Harry Suryapranata, Arnoud W. van t’ Hof, Jan C. Hoorntja, Menko- 
Jan de Boer, Jan-Henk Dambrink, Felix Zijlstra, Hospital De Weezenlanden, Zwolle, The 
Netherlands 
Background. Even if time-to-reperfuslon has been demonstrated to be a main predictor 
of outcome in patients with ST-elevation myocardial Infarction (STEMI) treated with 
thrombolysis, still controversial remains Its prognostic role in patients treated with primary 
angioplasty. 
Methods. A total of 1791 patfents with STEMI treated wth primary angioplasty at our 
Institution from 1994 to 2001, represent the population of the current study. All clinical, 
angiographic. and follow-up data were collected. According to time-to-reperfusion. 
patients were dwided in 4 groups: Group 1 (c 2 hours), Group 2 (2-4 hours), Group 3 (4. 
6 hours), Group 4 (> 6 hours). A multivariate analysis was performed to identify indepen- 
dent predictors of 30-day mortality. 
Results. At multivariate analysis, a time-to-reperiusion > 4 hours was an independent 
predictors of 30.day mortality. 
